AI life science startups are pivoting to develop their own drug programs. At MaRS Impact Health 2025, industry experts explored where the sector is headed.
Featuring:
Alexander Mosa – Chair and CSO, Biossil
Janet Bannister – Managing Partner, Staircase Ventures
Anthony de Fazekas – Partner, Mintz LLP
Mobeen Lalani – Manager, Technology and Venture Development, Toronto Innovation Acceleration Partners (TIAP)